Scientific deep-dive
GLP-1 Drugs and Bone: Fracture Risk, Density and What Was Measured
Across 25 studies there was no significant increase in fracture risk and lumbar bone density improved slightly. A 117-trial network analysis of 221,364 people found no GLP-1 signal either.
Losing weight quickly costs bone. That is established, it predates these drugs, and it is the reason the question gets asked. What the evidence shows so far is reassuring and narrower than it sounds: across 25 studies there was no significant increase in fracture risk, and lumbar spine bone density improved slightly.[1] The catch is that almost all of it was measured in people with type 2 diabetes, over follow-up its own authors call too short.
Why weight loss and bone are linked at all
Bone responds to load. Carrying more weight means the skeleton is loaded more, and it adapts by holding more mineral; take the weight off and some of that adaptation reverses. There is a second route through hormones (fat tissue produces estrogen, and estrogen protects bone) and a third through intake, since eating substantially less tends to mean less calcium, less protein and less vitamin D.
None of that is specific to these drugs. It is true of bariatric surgery and of successful dieting. Weight loss affects bone. The open question is whether these drugs add anything beyond that.
What the fracture data show
The broadest look is a network meta-analysis of 117 randomized trials covering 221,364 participants, comparing every class of diabetes drug against placebo on fracture risk.[2] GLP-1 drugs came out in the large middle group: comparable to placebo, no statistically significant difference.
One GLP-1 did show a significant benefit: albiglutide, at a risk ratio of 0.29.[2] It is named here and then set aside, because albiglutide was withdrawn from the market in 2018. A class-wide claim built on the one member nobody can prescribe would mislead.
What happened to bone density itself
A 2025 meta-analysis of 25 studies looked past fractures to the measurements underneath: bone mineral density and the biochemical markers of bone turnover.[1]
| Measure | Finding |
|---|---|
| Fracture risk | No significant increase |
| Lumbar spine bone density | Statistically significant improvement (mean difference 0.07 g/cm²) |
| Bone turnover markers | Significant improvement in β-CTX, P1NP, osteocalcin, bone-specific ALP and 25-OH-D |
Density improving rather than falling, in people losing weight, is not what the load hypothesis alone would predict. It is one reason researchers suspect GLP-1 signaling may act on bone directly. It is also a small mean difference, and the authors close by asking for higher-quality studies with longer follow-up before anyone draws firm conclusions.[1] A small study in people without a pancreas points partly elsewhere: blocking GIP, not GLP-1, blunted the usual drop in bone breakdown after a meal.
A 2026 study fills the gap that meta-analysis leaves, and the two are easier to read together. Researchers matched 255 people taking semaglutide or tirzepatide to 255 non-users by age, sex, BMI and diabetes status, with bone density scans before and after, over a median of 17 months.[3]
| Group | GLP-1 users | Matched non-users |
|---|---|---|
| Overall, hip and femoral neck | Declined significantly | Declined significantly, similar magnitude |
| Patients with diabetes, total hip | Similar between groups | — |
| Patients without diabetes, total hip | −1% | −0.6% (P = .04) |
Set that beside the meta-analysis. The 25-study meta-analysis was conducted in people with type 2 diabetes, and this study finds no difference in that group. Where it finds one is in people without diabetes. That group makes up most of those taking these drugs for weight, and it is the population the earlier evidence barely covers.
Within that group, weight loss tracked bone loss, with correlations of 0.32 at the hip and 0.17 at the femoral neck. Those explain roughly 10% and 3% of the variation respectively: a real link, but a weak one. The authors’ reading is that weight loss drives the bone loss rather than the drug acting directly, which is the load hypothesis again and is the reassuring interpretation.[3]
There is a caution in the other direction. If bone loss scales with weight loss, a cohort that lost 5% is the mildest possible test of it, and most people on these drugs lose considerably more.
Who the reassurance does not obviously cover
Both bodies of evidence come overwhelmingly from people with type 2 diabetes. Diabetes has its own complicated relationship with bone. Density is often normal or high while fracture risk is nonetheless elevated, which makes it an odd population from which to reassure everybody else.
- Postmenopausal women, where estrogen withdrawal drives bone loss through a different mechanism entirely. Our menopause article takes that up directly, and the menopause seller board prints both bone studies on this page next to its ranking.
- Older adults, where a fracture is not an equivalent event to a fracture at forty. Strength and frailty after 65 covers the falls side, which is at least as important as the bone side.
- Anyone with existing osteoporosis, osteopenia or a prior fragility fracture, who was not the population these trials recruited.
- People losing weight far faster than trial averages, which compounded dosing and dose-stacking can produce.
What you can act on
Not much of this changes what a sensible person does. Adequate protein, adequate calcium and vitamin D, and resistance training are the interventions with evidence behind them for protecting bone during weight loss, and they are the same ones that protect muscle (see lean mass and the protein calculator).
Before starting, not after a year, raise these with a prescriber: any previous fracture that happened without much force behind it, a family history of osteoporosis, and whether a baseline bone density scan makes sense for you. A measurement taken before is worth considerably more than one taken after.
Frequently Asked Questions
References
- 1.Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. 2025. PMID: 39985672.
- 2.Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis Frontiers in Endocrinology. 2021. PMID: 34721294.
- 3.Liu Y, Walzer D, Schmitz S, et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41655226.
Compare the sellers
Related research
GLP-1 Drugs and Headache: A Side Effect, and a Treatment
Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.
7 min read
Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off
Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.
10 min read
GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days
Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.
7 min read
GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk
A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.
6 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
GLP-1 Drugs After Menopause: The Group Taking Them Most, Studied Least
One review exists on GLP-1 drugs in peri- and postmenopausal women, and it opens by describing a paucity of data. This sets out what has to be borrowed from other populations, and which borrowings hold up.
8 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →CoreAge Rx
Flat-priced compounded semaglutide at $79 a month, any dose
From $79/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →